IFNGR1 and cancer: The results imply that the loss-of-function of IFNγR1 and (or) IFNγR2 renders cancer cells resistant to CD19-CAR T cell killing differently in addition to the IFNγR pathway mediates cell adhesion which finally affects cytotoxicity.